Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro

International Journal of Cancer

Volumn 73, Issue 6, 1997, Pages 875-879

  Brodowicz, Thomas ^a   Wiltschke, Christoph ^a   Budinsky, Alexandra C ^a   Krainer, Michael ^a   Steger, Günther G ^a   Zielinski, Christoph C ^a,b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST; BREAST TUMOR; CELL CULTURE; CELL DIVISION; CULTURE MEDIUM; CYTOLOGY; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PHYSIOLOGY; SOLUBILITY;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BREAST; BREAST NEOPLASMS; CELL DIVISION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; FEMALE; HUMANS; IMMUNOTHERAPY; RECEPTOR, ERBB-2; SOLUBILITY; TUMOR CELLS, CULTURED;

EID: 0031564215     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971210)73:6<875::AID-IJC19>3.0.CO;2-3     Document Type: Article

References (22)

1. COUSSKNS, L., YANG-FENG, T.L., LIAO, Y.C., CHEN, E., GRAY, A., McGRATH, J., SEEBURG, P.M., LIBERMAN, T.A., SCHLESSINGER, J. and FRANCKE, U., Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132-1139 (1985).
2. FRANK, H. and 15 OTHERS, Phase la/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. clin. Oncol., 13, 2281-2292 (1995).
3. GATANAGA, T., HWANG, C. and KOHR, W., Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc. nat. Acad. Sci. (Wash.), 87, 8781-8784 (1990).
4. HARWURTH, I.M., WELS, W., MARTE, B.M. and HYNES, N.E., Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function us partial ligand agonists. J. biol. Chem., 267, 15160-15167 (1992).
5. HARWERTH, I.M., WELS, W., SCHEEGEL, J., MÜLLER, M. and HYNES, N.E., Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Brit. J. Cancer, 68, 1140-1145 (1993).
6. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. cell Biol., 9, 1165-1172 (1989).
7. HYNES, N.E., GERBER, H.A., SAURER, S. and GRONER, B., Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J. cell. Biochem., 39, 167-173 (1989).
8. ISOLA, J.J., HOLLI, K., OKSA, H., TERAMOTO, Y. and KALLIONIEMI, O.P., Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer, 73, 652-658 (1994).
9. KANDL, H., SEYMOUR, L. and BEZWODA, W.R., Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Brit. J. Cancer, 70, 739-742 (1994).
10. KOIZUMI, K., DE NARDO, G.L., DE NARDO, S.J., HAYS, M.T., HINES, H.H., SCHEIBE, P.O., PENG, J.S., MACEY, D.J., TONAMI, N. and HISADA, K., Multicompartmental analysis of the kinetics of radioiodinated monoclonal antibody in patients with cancer. J. nucl. Med., 27, 1243-1254 (1986).
11. KRAINER, M., BRODOWICZ, T., ZEILLINGER, R., WILTSCHKE, C., SCHOLTEN, C., SEIFERT, M., KUBISTA, E. and ZIELINSKI, C.C., Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology (1997) (In press).
12. KRAUS, M.H., POPESCU, N.C., AMSBAUGH, S.C. and KING, C.R., Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J., 6, 605-610 (1987).
13. LEWIS, G.D., FIGARI, I., FENDLY, B., WONG, W.L., CARTER, P., GORMAN, C. and SHEPARD, H.M., Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother., 37, 255-263 (1993).
14. LIN, Y.J. and CLINTON, G.M., A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene, 6, 639-643 (1991).
15. erbB2. Science, 249, 1552-1555 (1990).
16. PUPA, S.M., MÉNARD, S., ANDREOLA, S. and COLNAGHI, M.I., Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res., 53, 5864-5866 (1993a).
17. PUPA, S.M., MÉNARD, S., MORELLI, D., POZZI, B., DE PALO, G. and COLNAGHI, M.I., The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene, 8, 2917-2923 (1993b).
18. RUBIN, L.A., JAY, G. and NELSON, D.L., The released interleukin-2 receptor binds interleukin-2 efficiently. J. Immunol., 137, 3841-3845 (1986).
19. SLAMON, D.J., CLARK, G.M., WONG, S.G., LEVIN, W.J., ULLRICH, A. and MCGUIRE, W.L., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/HCH oncogene. Science, 23, 177-182 (1987).
20. SLAMON, D.J., GODOLPHIN, W., JONES, L.A., HOLT, J.A., WONG, S.O., KEITH, D.E., LEVIN, W.J., STUART, S.G., UDOVE, J., ULLRICH, A. and PRESS, M.F., Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-712 (1989).
21. WILTSCHKE, C., KRAINER, M., BUDINSKY, A., BERGKR, A., MÜLLER, C., ZEILLINGER, R., SPEISER, P., KUBISTA, E., EIBL, M. and ZIELINSKI, C.C., Reduced mitogenic stimulation of peripheral blood munonucleur cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study. Brit. J. Cancer, 71, 1292-1296 (1995).
22. WU, J.T., ASTILL, M.E. and ZHANG, P., Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers. J. clin. Lab. Anal., 7, 31-40 (1993).